Atherosclerosis Drugs Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2027

Published on : Jan-2020 | List of Tables : 20 | List of Figures : 99 | No. of Pages : 170 | Report Code : FACT4434MR |

Atherosclerosis Drugs Market: Nanotechnology to Upgrade Quality of Drugs

Competency of nano polymers in imaging further broadens the scope of nanotechnology in the diagnosis of cardiovascular disorders, which makes it the present and the future technology of atherosclerosis drugs. Nanotechnology is adding a new paradigm in the development of atherosclerosis drugs, owing to its selective drug delivery system that only targets damaged tissues. One such nano polymer, E-selectin-targeting polymer, is used for imaging and drug delivery applications to improve the function of heart muscles.

Though technological advancements and demand for drugs are growing at a notable rate, a large number of individuals remain undiagnosed. Low diagnostic rates could hamper the growth potential of the atherosclerosis drugs market during the forecast period (2020-2027).

assessment of atherosclerosis drugs market by drug class

For detailed insights on market taxonomy, request a sample copy of the report here.

Retail Pharmacies Gaining Prominence in Atherosclerosis Drugs Market

Hospital pharmacies boast of well-stocked inventory with a wide range of prescribed and OTC medications, which makes it convenient for individuals to makes purchases immediately after diagnosis. Numerous government-held hospital pharmacies offer medications at low rates, which further becomes a viable sales opportunity. Hospital pharmacies are projected to account for around 46% share in the atherosclerosis drugs market by 2027. However, they could lose market share to retail pharmacies, to some extent, on the back of a large chain of retail pharmacies at key locations, which makes it easy for individuals to refill their drug supplies. Besides this, in recent times, retail pharmacists are also playing a consultative role, which is likely to influence reliance on retail pharmacies. On account of growing popularity, retail pharmacies are set to register a value equal to US$ 24 Bn by 2027.

key regions in atherosclerosis drugs market

For detailed regional analysis, request a sample copy of the report here.

Growing Popularity of Generic Drugs – A Concern for North America, an Opportunity for Asia Pacific

Powerful forces at play attributing a high share to the North American atherosclerosis drugs market majorly include large public funding. The American Heart Association actively supports the research & development endeavours of market players, intended towards improving the cardiovascular health of the U.S. population. Besides this, initiatives taken by the government to upgrade healthcare infrastructure and increase awareness regarding the treatment of numerous disorders are likely to augment diagnostic and drug adoption rates. On the back of numerous favourable drivers, the North America atherosclerosis drugs market is projected to account for 34% market share by 2027.

Though North America holds a leading position in the global atherosclerosis drugs market, increasing sales of generic drugs are impeding the revenue potential of leading players operating in this region. However, the Asia Pacific atherosclerosis drugs market is thriving on the back of growing sales of generic drugs, as a large number of prominent and emerging players are working towards their development. In addition, Asia Pacific is a price-sensitive region, wherein, affordability of individuals plays a pivotal role in their purchase decisions. Growing preference for generic drugs over branded ones, in parallel with rising awareness regarding atherosclerosis disorders, would create a conducive environment for market growth during the forecast period.

Atherosclerosis Drugs Market – Scope of the Report

The study on the atherosclerosis drugs market is an exclusive report published by Fact.MR, which brings to the fore crucial parameters that are driving the growth of the market. This exclusive study provides incisive insights regarding recent developments in the atherosclerosis drugs market, by analysing the historical data for the period of 2017-2019, and the duration of 2020-2027 that is considered as the forecast period.

Evaluation of the atherosclerosis drugs market’s revenue has been carried out in terms of value (US$ Mn). This research provides information into the key trends that are potential enough to influence the growth of the atherosclerosis drugs market. Besides this, the study also includes several macroeconomic and microeconomic growth indicators complementing the growth of the atherosclerosis drugs market during the forecast period. This detailed study provides information into key dynamics, and their influence on the atherosclerosis drugs market during the forecast period.

The report also provides information about the key challenges and threats that could deter the growth potential of players in the atherosclerosis drugs market. The study unveils profitable opportunities for manufacturers, which they can adopt to strengthen their position in the global atherosclerosis drugs market. With a view of aiding stakeholders in the atherosclerosis drugs market, the study comprises a detailed section on the competition analysis.

This exclusive study offers a dashboard view of the atherosclerosis drugs market, with detailed information about market players, based on overall revenue, key developments, and their market presence. Additionally, key strategies of players in the atherosclerosis drugs market have also been included in this comprehensive study.

Atherosclerosis Drugs Market – Assessment of Key Segments

Authors of this comprehensive study have classified the atherosclerosis drugs market into key segments for an in-depth study of the market. Categorisation of the atherosclerosis drugs market is based on drug class, distribution channel, and region. This detailed study also offers information about the incremental opportunity present in the atherosclerosis drugs market during the forecast period. Key segments considered while studying the atherosclerosis drugs market include:

Drug Class

Distribution Channel

Region

Anti-platelet Medications

Retail Pharmacies

North America

Cholesterol Lowering Medications

Hospital Pharmacies

Europe

Fibric Acid and Omega-3 Fatty Acid Derivatives

Online Pharmacies

Asia Pacific

Beta Blockers

 

Latin America

Angiotensin-converting Enzyme (ACE) Inhibitors

 

Middle East & Africa

Calcium Channel Blockers

 

 

Diuretics

 

 

Others

 

 

Revenue of the atherosclerosis drugs market has been evaluated in terms of US$ Mn for the period of 2020 to 2027. In addition to this, compound annual growth rate has been calculated for all key segments for the forecast period of 2020-2027, considering 2019 as the base year.

Authors of this exclusive study on the atherosclerosis drugs market have analysed key players, based on their financials, products, and strategies, in order to provide key detailed information into the competitive landscape. Key players operating in the atherosclerosis drugs market include Pfizer Inc., GlaxoSmithKline PLC, Amgen Inc., Sanofi, Mylan N.V., F.Hoffmann-La Roche Ltd., Janssen Pharmaceuticals, Inc., Bayer AG, Merck & Co., Inc., and Novartis AG.

This exclusive study is produced to offer a detailed perspective of the atherosclerosis drugs market to stakeholders, who include companies and intermediaries engaged in the development, manufacturing, and commercialisation of drugs. The report is also aimed at offering crucial information about the atherosclerosis drugs market to new players.

Atherosclerosis Drugs Market – Research Methodology

The primary objective of this exclusive study on the atherosclerosis drugs market is to offer precise estimates and forecasts of the market in terms of value (US$ Mn) for the period of 2020-2027. The secondary objective includes analysis of key market segments exhibiting significant growth rates, leading strategies adopted by players in the atherosclerosis drugs market, and the adoption rate of atherosclerosis drugs in key regions across the world.

1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Atherosclerosis Drugs Market

4. Market Overview

        4.1. Introduction

            4.1.1. Drug Type Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

                4.3.1.1. Increase in Prevalence of Atherosclerosis & Cardiovascular Diseases 

                4.3.1.2. Development of New Treatments 

                4.3.1.3. Rising Awareness about Cardiovascular Diseases 

            4.3.2. Restraints

                4.3.2.1.  Availability of Generic Products

                4.3.2.2.  Low Diagnostic Rate 

            4.3.3. Opportunities

        4.4. Global Atherosclerosis Drugs Market Analysis and Forecast, 2020–2027

5. Market Outlook

        5.1. Clinical Trial Pipeline Analysis

        5.2. Disease Prevalence & Incidence Rate globally with key countries

        5.3. Brand Analysis

6. Global Atherosclerosis Drugs Market Analysis and Forecast, By Drug Class 

        6.1. Introduction & Definition

            6.1.1. Key Findings / Developments

        6.2. Global Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2020–2027

            6.2.1. Anti-platelet Medications

            6.2.2. Cholesterol Lowering Medications

            6.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives

            6.2.4. Beta Blockers

            6.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors

            6.2.6. Calcium Channel Blockers

            6.2.7. Diuretics

            6.2.8. Others

        6.3. Global Atherosclerosis Drugs Market Attractiveness, by Drug Class 

7. Global Atherosclerosis Drugs Market Analysis and Forecast, By Distribution Channel 

        7.1. Introduction & Definition

            7.1.1. Key Findings / Developments

        7.2. Global Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2020–2027

            7.2.1. Retail Pharmacies

            7.2.2. Hospital Pharmacies

            7.2.3. Online Pharmacies 

        7.3. Global Atherosclerosis Drugs Market Attractiveness, by Distribution Channel 

8. Global Atherosclerosis Drugs Market Analysis and Forecast, By Region

        8.1. Key Findings

        8.2. Global Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Region 

            8.2.1. North America 

            8.2.2. Europe 

            8.2.3. Asia Pacific 

            8.2.4. Latin America 

            8.2.5. Middle East & Africa 

        8.3. Global Atherosclerosis Drugs Market Attractiveness, by region 

9. North America Atherosclerosis Drugs Market Analysis and Forecast

        9.1. Introduction

            9.1.1. Key Findings

        9.2. North America Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2020–2027

            9.2.1. Anti-platelet Medications

            9.2.2. Cholesterol Lowering Medications

            9.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives

            9.2.4. Beta Blockers

            9.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors

            9.2.6. Calcium Channel Blockers

            9.2.7. Diuretics

            9.2.8. Others

        9.3. North America Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2020–2027

            9.3.1. Retail Pharmacies

            9.3.2. Hospital Pharmacies

            9.3.3. Online Pharmacies 

        9.4. North America Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Country, 2020–2027

            9.4.1. U.S.

            9.4.2. Canada

        9.5. North America Atherosclerosis Drugs Market Attractiveness

            9.5.1. By Drug Type 

            9.5.2. By Distribution Channel 

            9.5.3. By Country

10. Europe Atherosclerosis Drugs Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Europe Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2020–2027

            10.2.1. Anti-platelet Medications

            10.2.2. Cholesterol Lowering Medications

            10.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives

            10.2.4. Beta Blockers

            10.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors

            10.2.6. Calcium Channel Blockers

            10.2.7. Diuretics

            10.2.8. Others

        10.3. Europe Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2020–2027

            10.3.1. Retail Pharmacies

            10.3.2. Hospital Pharmacies

            10.3.3. Online Pharmacies 

        10.4. Europe Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Country Sub/region, 2020–2027

            10.4.1. Germany

            10.4.2. U.K.

            10.4.3. France

            10.4.4. Spain

            10.4.5. Italy

            10.4.6. Rest of Europe

        10.5. Europe Atherosclerosis Drugs Market Attractiveness

            10.5.1. By Drug Type 

            10.5.2. By Distribution Channel 

            10.5.3. By Country/Sub-region

11. Asia Pacific  Atherosclerosis Drugs Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Asia Pacific Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2020–2027

            11.2.1. Anti-platelet Medications

            11.2.2. Cholesterol lowering medications

            11.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives

            11.2.4. Beta blockers

            11.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors

            11.2.6. Calcium Channel Blockers

            11.2.7. Diuretics

            11.2.8. Others

        11.3. Asia Pacific Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2020–2027

            11.3.1. Retail Pharmacies

            11.3.2. Hospital Pharmacies

            11.3.3. Online Pharmacies 

        11.4. Asia Pacific Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2020–2027

            11.4.1. China

            11.4.2. Japan

            11.4.3. India

            11.4.4. Australia & New Zealand

            11.4.5. Rest of Asia Pacific

        11.5. Asia Pacific Atherosclerosis Drugs Market Attractiveness

            11.5.1. By Drug Type 

            11.5.2. By Distribution Channel 

            11.5.3. By Country/Sub-region

12. Latin America Atherosclerosis Drugs Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Latin America Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2020–2027

            12.2.1. Anti-platelet Medications

            12.2.2. Cholesterol Lowering Medications

            12.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives

            12.2.4. Beta blockers

            12.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors

            12.2.6. Calcium Channel Blockers

            12.2.7. Diuretics

            12.2.8. Others

        12.3. Latin America  Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2020–2027

            12.3.1. Retail Pharmacies

            12.3.2. Hospital Pharmacies

            12.3.3. Online Pharmacies 

        12.4. Latin America Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2020–2027

            12.4.1. Brazil

            12.4.2. Mexico

            12.4.3. Rest of Latin America

        12.5. Latin America Atherosclerosis Drugs Market Attractiveness

            12.5.1. By Drug Type 

            12.5.2. By Distribution Channel 

            12.5.3. By Country/Sub-region

13. Middle East & Africa  Atherosclerosis Drugs Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Middle East & Africa Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2020–2027

            13.2.1. Anti-platelet medications

            13.2.2. Cholesterol Lowering Medications

            13.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives

            13.2.4. Beta blockers

            13.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors

            13.2.6. Calcium Channel Blockers

            13.2.7. Diuretics

            13.2.8. Others

        13.3. Middle East & Africa Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2020–2027

            13.3.1. Retail Pharmacies

            13.3.2. Hospital Pharmacies

            13.3.3. Online Pharmacies 

        13.4. Middle East & Africa Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2020–2027

            13.4.1. GCC 

            13.4.2. South Africa

            13.4.3. Rest of Middle East & Africa

        13.5. Middle East & Africa Atherosclerosis Drugs Market Attractiveness

            13.5.1. By Drug Type 

            13.5.2. By Distribution Channel 

            13.5.3. By Country/Sub-region

14. Competition Landscape

        14.1.   Market Player – Competition Matrix (By Tier and Size of companies)

        14.2. Key Company’s Market Ranking Analysis

        14.3. Company Profiles

            14.3.1. GlaxoSmithKline Plc

                14.3.1.1. Company Overview

                14.3.1.2. Company Financials

                14.3.1.3. Growth Strategies

                14.3.1.4. SWOT Analysis

            14.3.2. Sanofi

                14.3.2.1. Company Overview

                14.3.2.2. Company Financials

                14.3.2.3. Growth Strategies

                14.3.2.4. SWOT Analysis

            14.3.3. Hoffmann-La Roche Ltd

                14.3.3.1. Company Overview

                14.3.3.2. Company Financials

                14.3.3.3. Growth Strategies

                14.3.3.4. SWOT Analysis

            14.3.4. Bayer AG

                14.3.4.1. Company Overview

                14.3.4.2. Company Financials

                14.3.4.3. Growth Strategies

                14.3.4.4. SWOT Analysis

            14.3.5. Novartis AG

                14.3.5.1. Company Overview

                14.3.5.2. Company Financials

                14.3.5.3. Growth Strategies

                14.3.5.4. SWOT Analysis

            14.3.6. Merck & Co., Inc. (Merck Sharp & Dohme Corp)

                14.3.6.1. Company Overview

                14.3.6.2. Company Financials

                14.3.6.3. Growth Strategies

                14.3.6.4. SWOT Analysis

            14.3.7. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)

                14.3.7.1. Company Overview

                14.3.7.2. Company Financials

                14.3.7.3. Growth Strategies

                14.3.7.4. SWOT Analysis

            14.3.8. Mylan N.V. 

                14.3.8.1. Company Overview

                14.3.8.2. Company Financials

                14.3.8.3. Growth Strategies

                14.3.8.4. SWOT Analysis

            14.3.9. Amgen Inc.

                14.3.9.1. Company Overview

                14.3.9.2. Company Financials

                14.3.9.3. Growth Strategies

                14.3.9.4. SWOT Analysis

            14.3.10. Pfizer, Inc.

                14.3.10.1. Company Overview

                14.3.10.2. Company Financials

                14.3.10.3. Growth Strategies

                14.3.10.4. SWOT Analysis

Fact.MR offers custom research services that help clients to get specific research solutions

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Atherosclerosis Drugs Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2027